Literature DB >> 7684596

Hyaluronan and hyaluronectin in the extracellular matrix of human brain tumour stroma.

B Delpech1, C Maingonnat, N Girard, C Chauzy, R Maunoury, A Olivier, J Tayot, P Creissard.   

Abstract

Hyaluronan (HA) and the hyaluronan-binding glycoprotein hyaluronectin (HN) were measured in 23 gliomas and 8 meningiomas and their location was revisited in 35 tumours. A clear-cut difference was found in the HN/HA ratio values of glioblastomas (below 0.5) and that of astrocytomas (above 0.5 P < 0.001). Besides their location in the intercellular part of gliomas, HA and HN displayed a perivascular location in 1/3 astrocytomas, 17/24 glioblastomas, and 3/7 meningiomas, suggesting they could be produced also by the vascular stroma of tumours and that they would characterise the neoangiogenesis. All cultivated glioma cells tested produced HA in vitro, whereas only 1/11 cell lines produced HN, at a low level. The results obtained suggest that glioma HA and HN are produced by both cancer cells and vascular stroma cells, which contribute to the edification of the extracellular matrix. In meningiomas only the stroma would be responsible for HA and HN production.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684596     DOI: 10.1016/s0959-8049(05)80214-x

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  47 in total

1.  Tackling gliomas with nanoformulated antineoplastic drugs: suitability of hyaluronic acid nanoparticles.

Authors:  M Ganau
Journal:  Clin Transl Oncol       Date:  2013-09-27       Impact factor: 3.405

2.  Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles.

Authors:  Keith B Neeves; Andrew J Sawyer; Conor P Foley; W Mark Saltzman; William L Olbricht
Journal:  Brain Res       Date:  2007-08-29       Impact factor: 3.252

3.  Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform.

Authors:  Badriprasad Ananthanarayanan; Yushan Kim; Sanjay Kumar
Journal:  Biomaterials       Date:  2011-08-05       Impact factor: 12.479

Review 4.  Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion.

Authors:  W Knudson
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

5.  Effect of matrix metalloproteinase-mediated matrix degradation on glioblastoma cell behavior in 3D PEG-based hydrogels.

Authors:  Christine Wang; Xinming Tong; Xinyi Jiang; Fan Yang
Journal:  J Biomed Mater Res A       Date:  2016-11-18       Impact factor: 4.396

Review 6.  Targeting hyaluronan interactions in spinal cord astrocytomas and diffuse pontine gliomas.

Authors:  Bernard L Maria; Nalin Gupta; Anne G Gilg; May Abdel-Wahab; Anthony P Leonard; Mark Slomiany; William G Wheeler; Lauren B Tolliver; Michael A Babcock; John T Lucas; Bryan P Toole
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

7.  The hyaluronan receptor RHAMM/IHABP in astrocytoma cells: expression of a tumor-specific variant and association with microtubules.

Authors:  Rixin Zhou; Xiao Wu; Omar Skalli
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

8.  Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion.

Authors:  Bin Hu; Keerthi K Thirtamara-Rajamani; Hosung Sim; Mariano S Viapiano
Journal:  Mol Cancer Res       Date:  2009-11-03       Impact factor: 5.852

9.  Soft Substrates Containing Hyaluronan Mimic the Effects of Increased Stiffness on Morphology, Motility, and Proliferation of Glioma Cells.

Authors:  Katarzyna Pogoda; Robert Bucki; Fitzroy J Byfield; Katrina Cruz; Tongkeun Lee; Cezary Marcinkiewicz; Paul A Janmey
Journal:  Biomacromolecules       Date:  2017-09-14       Impact factor: 6.988

10.  CD44-mediated adhesion to hyaluronic acid contributes to mechanosensing and invasive motility.

Authors:  Yushan Kim; Sanjay Kumar
Journal:  Mol Cancer Res       Date:  2014-06-24       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.